- Malaria:MedlinePlus
- CDC –Malaria - Centers for Disease Control and Prevention. Comprehensive clinical resource on malaria.
- Malaria –Chapter 3 –2012 Yellow Book –Travelers’Health –CDC - Centers for Disease Control and Prevention. Comprehensive resource guide on malaria for travelers’health.
- WHO | Malaria - World Health Organization. Comprehensive global resource.
- WHO | The Malaria Eradication Research Agenda (malERA) initiative - World Health Organization -
“A collection of 12 reviews,comprising three reflective pieces and nine research and development agendas,is published as part of a sponsored Supplement on 25 January 2011 in PLoS Medicine. This Collection highlights the outcomes of a series of consultations among more than 250 experts that were undertaken by the Malaria Eradication Research Agenda (malERA) initiative”
- Malaria - eMedicine - Academic clinical resource on malaria and related topics. Registration required.
- Emergent Management of Malaria - eMedicine - Academic clinical discussion on malaria treatment. Registration required.
- Homepage • Malaria Nexus • Elsevier’s Global Malaria Resource - Comprehensive malaria resource. Registration required but journal article access may require subscritption.
- AnoBase:The Anopheles database -
“AnoBase is a database containing genomic/biological information on anopheline mosquitoes,with an emphasis on Anopheles gambiae,the world’s most important malaria vector. AnoBase is the continuation of AnoDB,a database established and maintained since 1996 at the Institute of Molecular Biology and Biotechnology (IMBB) of the Foundation of Research and Technology –Hellas (FORTH) in Heraklion,Crete,Greece.”
“PlasmoDB is a genome database for the genus Plasmodium,
a set of single-celled eukaryotic pathogens that cause human and animal
diseases,including malaria.”Malaria National
Institute of Allergy and Infectious Diseases (NIAID) National Institutes
of Health (NIH)
NIAID Malaria Research Program
“Nearly one million people die of malaria every year,mostly
infants,young children,and pregnant women,and most of them in
Africa. Finding effective ways to control and eventually eradicate
the disease is a high priority of NIAID.”Excellent videos as well.
infants,young children,and pregnant women,and most of them in
Africa. Finding effective ways to control and eventually eradicate
the disease is a high priority of NIAID.”Excellent videos as well.
- Malaria –NHS Choices - National Health Service –Excellent collection of malaria resources with an informational
video. - Malaria Parasite Metabolic Pathways - The Hebrew University of Jerusalem,Israel. Comprehensive resource for biochemistry and physiology for malaria.
- MALARIA.COM | Malaria Information,Research and News - Excellent collection of clinical and research resources for
malaria. - Home – Malaria Atlas Project
“The Malaria Atlas Project aims to disseminate free,accurate and
up-to-date information on malaria and associated topics,organised
on a geographical basis.” Excellent
resource.
“The PATH Malaria Vaccine Initiative (MVI) is a global
program of the international nonprofit organization PATH.
MVI was established in 1999 through a grant from the
Bill &Melinda Gates Foundation.
program of the international nonprofit organization PATH.
MVI was established in 1999 through a grant from the
Bill &Melinda Gates Foundation.
Our mission: To accelerate the development
of malaria vaccines and ensure their availability and
accessibility in the developing world.
of malaria vaccines and ensure their availability and
accessibility in the developing world.
Our vision: A world free from malaria.”
The New England Journal of Medicine –Nov. 17,2011
Nicholas J. White,F.R.S.
“All the investigators who have labored long and hard
in the development and evaluation of this malaria vaccine
deserve congratulations. It is a great achievement and
an important advance,but they know that this partially
protective vaccine is not the sole solution to the control
and elimination of malaria. After registration,the definitive
WHO guidance,expected in 2015,may recommend that the
inclusion of RTS,S/AS01 in the multipronged attack against
malaria is justified. The key question of how long the
protection against malaria lasts,particularly in the
anticipated context of declining malaria transmission,
remains open. An assessment of an 18-month booster dose
will not be available until 2014. Another key issue is
whether efficacy varies according to the intensity of
transmission. We also do not know yet how much the vaccine
will cost. All these factors are essential components
of the objective assessments of cost-effectiveness that
should form the basis of future global and national policy
decisions.”
in the development and evaluation of this malaria vaccine
deserve congratulations. It is a great achievement and
an important advance,but they know that this partially
protective vaccine is not the sole solution to the control
and elimination of malaria. After registration,the definitive
WHO guidance,expected in 2015,may recommend that the
inclusion of RTS,S/AS01 in the multipronged attack against
malaria is justified. The key question of how long the
protection against malaria lasts,particularly in the
anticipated context of declining malaria transmission,
remains open. An assessment of an 18-month booster dose
will not be available until 2014. Another key issue is
whether efficacy varies according to the intensity of
transmission. We also do not know yet how much the vaccine
will cost. All these factors are essential components
of the objective assessments of cost-effectiveness that
should form the basis of future global and national policy
decisions.”
